^
BIOMARKER:

KRAS G12C

i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
KRAS G12C
CRC
bevacizumab
Resistant: C3 – Early Trials
Frontiers - 2 weeks
KRAS G12C
NSCLC
sotorasib
Sensitive: A1 - Approval
KRAS G12C
NSCLC
Immunotherapy
Sensitive: B - Late Trials
KRAS G12C
NSCLC
MRTX849
Sensitive: B - Late Trials
KRAS G12C
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive: B - Late Trials
KRAS G12C
NSCLC
abemaciclib
Sensitive: B - Late Trials
KRAS G12C
NSCLC
pembrolizumab
Sensitive: B - Late Trials
KRAS G12C
CRC
cetuximab
Resistant: B - Late Trials
KRAS G12C
CRC
panitumumab
Resistant: B - Late Trials
KRAS G12C
Ampulla of Vater Carcinoma
sotorasib
Sensitive: C1 - Off-label
KRAS G12C
Pancreatic Cancer
sotorasib
Sensitive: C1 - Off-label
KRAS G12C
Melanoma
sotorasib
Sensitive: C1 - Off-label
KRAS G12C
Endometrial Cancer
sotorasib
Sensitive: C1 - Off-label
KRAS G12C
CRC
sotorasib
Sensitive: C1 - Off-label
KRAS G12C
Gastrointestinal Cancer
sotorasib
Sensitive: C1 - Off-label
KRAS G12C
CRC
cetuximab + MRTX849
Sensitive: C2 – Inclusion Criteria
KRAS G12C
NSCLC
sotorasib + VS-6766
Sensitive: C2 – Inclusion Criteria
KRAS G12C
Solid Tumor
D-1553
Sensitive: C2 – Inclusion Criteria
KRAS G12C
Lung Cancer
D-1553
Sensitive: C2 – Inclusion Criteria
KRAS G12C
CRC
MEK inhibitor + sotorasib
Sensitive: C2 – Inclusion Criteria
KRAS G12C
NSCLC
SAR442720
Sensitive: C2 – Inclusion Criteria
KRAS G12C
NSCLC
selumetinib
Sensitive: C3 – Early Trials
KRAS G12C
Cholangiocarcinoma
MRTX849
Sensitive: C3 – Early Trials
KRAS G12C
Ovarian Cancer
MRTX849
Sensitive: C3 – Early Trials
KRAS G12C
Pancreatic Cancer
MRTX849
Sensitive: C3 – Early Trials
KRAS G12C
Endometrial Cancer
MRTX849
Sensitive: C3 – Early Trials
KRAS G12C
CRC
MRTX849
Sensitive: C3 – Early Trials
KRAS G12C
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
KRAS G12C
Solid Tumor
IN10018 + MRTX1257
Sensitive: C3 – Early Trials
KRAS G12C
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS G12C
NSCLC
erlotinib
Resistant: C3 – Early Trials
KRAS G12C
Gastrointestinal Cancer
sotorasib + AbGn-107
Sensitive: C3 – Early Trials
KRAS G12C
CRC
panitumumab + sotorasib
Sensitive: C3 – Early Trials
KRAS G12C
NSCLC
lorlatinib
Resistant: C3 – Early Trials
KRAS G12C
NSCLC
crizotinib
Resistant: C4 – Case Studies
KRAS G12C
LUAD
MRTX849 + TVB-3664
Sensitive: D – Preclinical
KRAS G12C
Pancreatic Cancer
sotorasib + SNS-510
Sensitive: D – Preclinical
KRAS G12C
NSCLC
sotorasib + SNS-510
Sensitive: D – Preclinical
KRAS G12C
NSCLC
sotorasib + TPX-0005
Sensitive: D – Preclinical
KRAS G12C
Solid Tumor
sotorasib + IN10018
Sensitive: D – Preclinical
KRAS G12C
Solid Tumor
PD-0325901 + BGB-283
Sensitive: D – Preclinical
KRAS G12C
CRC
regorafenib
Resistant: D – Preclinical
KRAS G12C
CRC
sunitinib
Resistant: D – Preclinical
KRAS G12C
NSCLC
sotorasib + VS-6766 + MRTX849
Sensitive: D – Preclinical
KRAS G12C
CRC
sotorasib + VS-6766 + MRTX849
Sensitive: D – Preclinical
KRAS G12C
NSCLC
sotorasib + VS-6766 + VS-6063
Sensitive: D – Preclinical
KRAS G12C
NSCLC
selinexor + MRTX1257
Sensitive: D – Preclinical
KRAS G12C
Lung Cancer
afatinib + sotorasib
Sensitive: D – Preclinical
KRAS G12C
Lung Cancer
sotorasib + RMC-4550
Sensitive: D – Preclinical
KRAS G12C
Lung Cancer
palbociclib + sotorasib
Sensitive: D – Preclinical
KRAS G12C
CRC
D-1553
Sensitive: D – Preclinical
KRAS G12C
NSCLC
sotorasib + selinexor
Sensitive: D – Preclinical
KRAS G12C
Pancreatic Ductal Adenocarcinoma
sotorasib + selinexor
Sensitive: D – Preclinical
KRAS G12C
Pancreatic Ductal Adenocarcinoma
selinexor + MRTX1257
Sensitive: D – Preclinical
KRAS G12C
Pancreatic Cancer
D-1553
Sensitive: D – Preclinical
KRAS G12C
CRC
trametinib + panitumumab + sotorasib
Sensitive: D – Preclinical
KRAS G12C
CRC
trametinib + sotorasib
Sensitive: D – Preclinical
KRAS G12C
Pancreatic Adenocarcinoma
ASN007
Sensitive: D – Preclinical